Kangtai Bio

Shenzhen Kangtai Biological Products Co., Ltd. (300601) was established in 1992, focusing on the research, development, production, and sales of human vaccines. It has now become one of the leading innovative biopharmaceutical enterprises in China with strong R&D capabilities, a comprehensive product portfolio, continuously expanding industrial scale, and significant progress in internationalization.

The company has five major R&D and industrial bases in Beijing and Shenzhen, including: Kangtai Biological Headquarters Base in Nanshan District, Shenzhen; New Vaccine R&D and Production Base in Nanshan District, Shenzhen; Kangtai Biological Park in Guangming District, Shenzhen; Beijing Minhai Biological Vaccine Industrial Base; and Minhai Biological New Vaccine International Industrial Base. It also has diverse R&D platforms including live attenuated viral vaccines, combined live attenuated viral vaccines, inactivated viral vaccines, genetically engineered vaccines, bacterial polysaccharide vaccines, multivalent bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, multivalent bacterial polysaccharide conjugate vaccines, combined vaccines, viral vector vaccines, mRNA vaccines, novel adjuvant technology, and recombinant protein vaccines, laying a solid foundation for the translation of cutting-edge vaccine technology achievements.

The company has 11 products on the market or with drug registration approvals, including core products such as 60-microgram hepatitis B vaccine, quadrivalent combined vaccine, dual-carrier 13-valent pneumococcal conjugate vaccine, and "four-dose regimen" human diploid cell rabies vaccine. Its marketing and distribution network covers 31 provinces (autonomous regions and municipalities) in China. In addition, it holds more than 80 patents and has more than 30 products in development, including pentavalent combined vaccine, quadrivalent influenza vaccine, recombinant RSV vaccine, recombinant herpes zoster vaccine, 20-valent pneumococcal polysaccharide conjugate vaccine, and measles-mumps-rubella live attenuated vaccine, covering almost all mainstream vaccine types worldwide. Moreover, it has multiple R&D platforms such as academician expert workstation, postdoctoral research workstation, Shenzhen New Vaccine Engineering Laboratory, and Beijing Engineering Technology Research Center for New Combined Vaccines, which continuously enhance the company's innovation capability.

The company adheres to both "bringing in" and "going global" strategies, steadily advancing its internationalization. Since its establishment, the company has undertaken technology transfer from all four international vaccine giants to China: Merck (US), Sanofi Pasteur (France), INTRAVACC (Netherlands), and AstraZeneca (UK). It has also carried out various forms of overseas cooperation such as finished product export and technology transfer with many "Belt and Road" countries including Indonesia, Pakistan, India, and Egypt.

In recent years, Kangtai Bio has been awarded honors including National Enterprise Technology Center, National High-tech Enterprise, Special Prize for Science and Technology Progress of Guangdong Preventive Medicine Association, First Prize of Shenzhen Science and Technology Progress Award, and Xinhua Net's "Outstanding ESG Social Responsibility Practice Case", receiving wide recognition from society for the social value and economic benefits created in the field of infectious disease prevention.

Looking to the future, Kangtai Bio will continue to adhere to the "lifeline" of quality assurance, strengthen R&D innovation as the "driving force", and expand new paths of international cooperation, contributing greater strength to global public health.